- Home
- FTDR vs PTGX Comparison
FTDR vs PTGX Comparison
Compare FTDR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- PTGX
- Stock Information
- Founded
- FTDR 1971
- PTGX 2006
- Country
- FTDR United States
- PTGX United States
- Employees
- FTDR N/A
- PTGX N/A
- Industry
- FTDR Diversified Commercial Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- PTGX Health Care
- Exchange
- FTDR Nasdaq
- PTGX Nasdaq
- Market Cap
- FTDR 2.9B
- PTGX 2.8B
- IPO Year
- FTDR 2018
- PTGX 2016
- Fundamental
- Price
- FTDR $53.47
- PTGX $43.92
- Analyst Decision
- FTDR Hold
- PTGX Strong Buy
- Analyst Count
- FTDR 5
- PTGX 8
- Target Price
- FTDR $46.50
- PTGX $66.50
- AVG Volume (30 Days)
- FTDR 917.6K
- PTGX 1.1M
- Earning Date
- FTDR 05-01-2025
- PTGX 05-06-2025
- Dividend Yield
- FTDR N/A
- PTGX N/A
- EPS Growth
- FTDR 34.69
- PTGX N/A
- EPS
- FTDR 3.08
- PTGX 0.86
- Revenue
- FTDR $1,891,000,000.00
- PTGX $207,801,000.00
- Revenue This Year
- FTDR $11.77
- PTGX N/A
- Revenue Next Year
- FTDR $6.46
- PTGX $7.13
- P/E Ratio
- FTDR $17.41
- PTGX $50.92
- Revenue Growth
- FTDR 5.58
- PTGX N/A
- 52 Week Low
- FTDR $32.95
- PTGX $24.22
- 52 Week High
- FTDR $63.49
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- FTDR 81.82
- PTGX 46.05
- Support Level
- FTDR $40.11
- PTGX $41.29
- Resistance Level
- FTDR $53.97
- PTGX $46.12
- Average True Range (ATR)
- FTDR 1.71
- PTGX 1.78
- MACD
- FTDR 1.59
- PTGX -0.17
- Stochastic Oscillator
- FTDR 96.71
- PTGX 43.48
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.